Healthcare
Precipio, Inc.(PRPO)
Live Price
Offline$22.45
+0.40% today
1Y Change
+110.51%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $60.00M
- Revenue Growth
- +50.6%
- EPS Growth
- +92.2%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Precipio, Inc. (PRPO) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $22.45 and up 110.5% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +50.6%, EPS growth of +92.2%, a dividend yield of 0.0%. What stands out right now is revenue +50.6%, EPS +92.2%, free cash flow +66.2% with operating margin -5.0% and ROIC -6.6%. Valuation is more restrained than many high-expectation growth names at price/sales 2.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PRPO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+50.6% vs +7.6% peer median
Operating Margin
Below sector median
-5.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 30, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +50.6% and EPS at +92.2%, with operating margin around -5.0%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 30, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +15.9% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 30, 2026 | โ | +4.6% | +19.2% | +32.8% |
2025 Nov 14, 2025 | โ | +8.8% | +26.7% | +24.5% |
2025 Aug 13, 2025 | โ | +2.9% | +1.7% | +41.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRPO
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PRPO Max Drawdown
-31.73%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PRPO and SPY.
Company Overview
Precipio, Inc.
NASDAQ Capital Market
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
- Leadership
- Ilan Danieli
- IPO Date
- Jun 30, 2017
- Employees
- 54
- Street Address
- 4 Science Park
- Mailing
- New Haven, CT, 06511
- Region
- New Haven, CT, US
- Reporting Currency
- USD
- Investor Line
- 203 787 7888
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 36.1
- Price/Sales
- 2.3
- Price/Book
- 3.4
Growth
- Revenue
- +50.6%
- EPS
- +92.2%
- Free Cash Flow
- +66.2%
Profitability
- Gross Margin
- 44.5%
- Operating Margin
- -5.0%
- Net Margin
- -1.5%
- ROE
- -2.8%
- ROIC
- -6.6%
Balance Sheet
- Debt/Equity
- 0.25
- Current Ratio
- 1.61
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.